Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Welcure Drugs & Pharmaceuticals Limited specializes in the manufacturing and distribution of generic pharmaceuticals, primarily targeting the Indian market. The company has a competitive edge in its low-cost production capabilities and a growing portfolio of over 200 products, including anti-infectives and cardiovascular medications.
Welcure generates revenue primarily through the sale of generic drugs, leveraging its cost-effective manufacturing processes to maintain competitive pricing. The company benefits from a strong distribution network across India, allowing it to capture market share in a rapidly growing pharmaceutical sector.
Regulatory approvals for new generic drugs
Market share changes in the Indian pharmaceutical sector
Pricing pressures from competitors
Supply chain disruptions affecting raw material costs
Regulatory changes impacting drug approval processes
Technological disruption in drug manufacturing
Increased competition from domestic and international generic manufacturers
Potential for price wars in key therapeutic categories
Negative operating margins leading to liquidity concerns
Dependence on a limited number of key products for revenue
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by GDP fluctuations.
low - The company is not heavily reliant on debt financing, thus rising interest rates have minimal impact on its cost structure or demand.
minimal - With a debt/equity ratio of 0.00, the company does not face significant credit risk.
growth - Investors may be attracted to potential revenue growth given the company's recent expansion efforts.
high - The stock has exhibited high volatility, particularly with a 1-year return of -97.9%.
